October's Top Growth Stocks for 2023

Despite historical market crashes in October, it is one of the better months for stocks historically, especially at the start of the fourth quarter Read More

[{"selector":"#anim-d30c0b0a-fa97-4abf-a0fc-f251f4e93106 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(-15.119733614327984%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-0e7caaa2-0fae-4f6f-8420-e4f229cf1116","keyframes":{"transform":["translate3d(-109.1954%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-3b316668-e048-4e39-8c60-222b7b569eba","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-1b4602eb-6422-4103-8fb0-9480d195349c","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] [{"selector":"#anim-d210ae95-b057-4d51-891d-5f6a85f741b3","keyframes":{"transform":["translate3d(115.55555%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-4dd89f60-895b-4442-b80e-43aae2fb1137","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-d5b53e47-84ea-4201-b8fb-7168cc60110f","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] October tends to be one of the better-performing periods for U.S. equities over the last century Read More

[{"selector":"#anim-14bf59a0-33f3-4a40-b64d-73dd596be202 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(-15.119733614327984%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-a3ca44e7-4ece-4ae8-a332-36e2fff4208f","keyframes":{"transform":["translate3d(-109.1954%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-e8163aa3-fc3e-40c7-91d8-a74243b174cc","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-ffd86853-36a3-4e47-a54a-d183890d876a","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] [{"selector":"#anim-c534b0cf-b470-4f64-a228-2e8cef365911","keyframes":{"transform":["translate3d(115.55555%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-2db9d008-05df-45e6-b850-2a534d1c35b9","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-86745ab7-0a93-41fc-9051-0c909e5e8f0f","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] Three top growth stock picks for the final quarter of 2023 are CRISPR Therapeutics (CRSP), DraftKings (DKNG), and Roivant Sciences Read More

[{"selector":"#anim-1b3b8000-8fbf-4414-b444-ec70ecd92b18 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(-15.119733614327984%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-d69c497c-1158-4a36-820e-ac382017962a","keyframes":{"transform":["translate3d(-109.1954%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-dad264d0-e102-4e98-a782-be73ae7dc25d","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-c5c9d58a-e2c0-4baf-b8cb-fc593ca6eb62","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] [{"selector":"#anim-193783d4-9331-469e-ac6a-5fb0f0b312a5","keyframes":{"transform":["translate3d(115.55555%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-854fd114-e7e1-46b8-b4df-e88c98c96f8e","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-1b33cac1-abb2-4d9a-8cae-6725ede319f4","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] CRISPR Therapeutics and Vertex Pharmaceuticals are awaiting FDA decisions on their CRISPR/Cas9 gene-edited sickle cell disease candidate, exa-cel, in December 2023 Read More

[{"selector":"#anim-d7e9ed72-ed7b-4144-87c1-34952d197b75 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(-15.119733614327984%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-41b01d58-b32b-4e73-a61d-4d0abbd8572e","keyframes":{"transform":["translate3d(-109.1954%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-aa6936f9-1e22-45a0-a9af-ab1149c55ee7","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-3d4f0c87-abf4-498b-bf7a-d3c3d26e5fde","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] [{"selector":"#anim-1d9dfac9-7e35-4f4f-9882-4020e698f0c2","keyframes":{"transform":["translate3d(115.55555%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-8718a8b1-76ea-4c76-80ec-230f5ea02430","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-bddd79b1-10c2-4150-8f97-f836e025c69b","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] In March 2024, the FDA is expected to decide on exa-cel's second indication for a rare blood disorder known as transfusion-dependent beta-thalassemia Read More

[{"selector":"#anim-338f1960-6445-4e7a-a1c1-c5634e630d92 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(-15.119733614327984%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-695d20e0-f757-4c2e-b525-da3806821720","keyframes":{"transform":["translate3d(-109.1954%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-a3e23cfe-2a23-4027-a2b7-712ba38830cf","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-bc03778c-2b42-4be6-b73d-26637da25f3b","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] [{"selector":"#anim-4b556939-3308-463b-9097-30685d7345c4","keyframes":{"transform":["translate3d(115.55555%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-754848e8-3f53-42aa-92e1-ef74b2e0b9ed","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-6488f1fc-371a-49ea-97f6-926713564397","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] DraftKings has seen a remarkable 154% increase in its stock value in 2023, driven by continuous revenue growth in the online gaming and sports-betting industry Read More

[{"selector":"#anim-183b1bc2-0873-464a-931b-be154002852e [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(-15.119733614327984%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-64881571-2b0c-4545-9cd8-0ba32100af04","keyframes":{"transform":["translate3d(-109.1954%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-d6fe0bf4-f28b-43a1-9696-0f6cc1936816","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-7857d0de-e731-4939-ab59-0723cec69438","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] [{"selector":"#anim-b6c4597b-5da2-41f0-80fc-1544e9b093f7","keyframes":{"transform":["translate3d(115.55555%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f0ca51dc-a9f1-4d1a-9b5c-8d6a8bcf32da","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-551f743b-3c06-45cb-8f96-3145857a761d","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] DraftKings is positioned to benefit from the rapid growth of the online sports betting industry, potentially doubling its annual revenue by the end of the decade Read More

[{"selector":"#anim-8b276cac-e7e3-4213-bf58-d0bf7a22e119 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(-15.119733614327984%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-f7f22ee3-5de8-46ce-87d1-6f76f7d2f6ee","keyframes":{"transform":["translate3d(-109.1954%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-8a34baad-c582-49d5-8613-e01758bd82e1","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-b179e59f-a4eb-4ed2-988f-0c4de9a5ddd7","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] [{"selector":"#anim-83716d2c-679b-447a-a3bb-411e457333e0","keyframes":{"transform":["translate3d(107.37463%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-4c9b53e9-fc78-4c44-9889-d73f665498a0","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-78cd679f-858f-48b7-b9bb-180b5789260e","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] Roivant Sciences employs a unique strategy of building specialized units called "vants" to accelerate drug development and has seen a 276% increase in stock value over the past year Read More

[{"selector":"#anim-6c39f1cc-fca7-4c4d-88b6-4d4575f8a740 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(-15.119733614327984%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-5c21934b-de46-436e-81fd-8ab99dce421c","keyframes":{"transform":["translate3d(-109.1954%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-2c367b04-8f25-49d6-b193-4bb4960a03af","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-2ec8eac8-18c4-4c76-801a-c15ef12d2cec","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] [{"selector":"#anim-9dfa0541-dbac-4d69-a585-ca1c67e08acd","keyframes":{"transform":["translate3d(107.37463%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-19e871c5-bc86-41a7-98e8-dc4fcad6c97b","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-9a91f0af-9375-41f2-9e0e-8eb1def587d4","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] Roivant Sciences has two promising immunology drugs under its portfolio, including RVT-3101 and Immunovant's IMVT-1402 Read More

[{"selector":"#anim-4824bcc8-fef4-4fa5-8c10-c86a11525a91 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate(-15.119733614327984%, 0%) scale(1.5)","translate(0%, 0%) scale(1)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-61326be8-19cf-487d-804d-a3befec9e299","keyframes":{"transform":["translate3d(-109.1954%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-a50b15f0-9e99-4e05-ac88-8920b9f824ee","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-596f3345-c6ee-477e-b024-709da09f3b31","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] [{"selector":"#anim-10207fb3-db4d-4366-bec6-d6821f6e2559","keyframes":{"transform":["translate3d(107.37463%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-70d655fa-bc69-45d6-a397-d41e43c61e12","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-d734e4bf-80b9-4531-9cb6-deb0f56b57c4","keyframes":{"transform":["scale(0.15)","scale(1)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"forwards"}] Despite its significant growth potential, Roivant Sciences' current market cap is just under $10 billion, making it an attractive option for long-term investors Read More